ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
Projected Number of People With Onchocerciasis-Loiasis Coinfection in Africa, 1995 to 2025.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 6 citations in OpenAlex.
- From the Laboratory to the Field: Assessing the Usability of the NTDscope in the Tropical Rainforest Region of Gabon.The American journal of tropical medicine and hygiene · 2026Article
- Nodding Syndrome: The Need to Strengthen Epilepsy Care in Onchocerciasis-Endemic Areas and to Investigate the Pathogenesis of Onchocerciasis-Associated Epilepsy.The American journal of tropical medicine and hygiene · 2026Article
- HISTONCHO: A dataset of intervention histories for onchocerciasis control & elimination in sub-Saharan Africa.Scientific data · 2026Article
- Revisiting the Loa loa microfilaremia thresholds above which serious adverse events may occur with ivermectin treatment.PLoS neglected tropical diseases · 2025Article
- Model-Based Geostatistical Mapping of the Prevalence of Onchocerca volvulus in Cameroon between 1971 and 2020.PLoS neglected tropical diseases · 2025Article
- Clinical and epidemiological features of imported loiasis in Beijing: a report from patients returned from Africa.BMC infectious diseases · 2024Article
- A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity.PLoS neglected tropical diseases · 2023Article
- Cases of Loiasis Among a Congolese Family: Screening for Loiasis Among Newly Arrived Refugees From Endemic Areas.The journal for nurse practitioners : JNP · 2023Article
- Excess Mortality Associated With Loiasis: Confirmation by a New Retrospective Cohort Study Conducted in the Republic of Congo.Open forum infectious diseases · 2023Article
- Application of loop mediated isothermal amplification (LAMP) assays for the detection ofFrontiers in tropical diseases · 2023Article
- The prevalence of onchocerciasis in Africa and Yemen, 2000-2018: a geospatial analysis.BMC medicine · 2022Article
- Geostatistical modelling enables efficient safety assessment for mass drug administration with ivermectin in Loa loa endemic areas through a combined antibody and LoaScope testing strategy for elimination of onchocerciasis.PLoS neglected tropical diseases · 2022Article
- Evaluation of the in vitro susceptibility of various filarial nematodes to emodepside.International journal for parasitology. Drugs and drug resistance · 2021Article
- The burden of skin disease and eye disease due to onchocerciasis in countries formerly under the African Programme for Onchocerciasis Control mandate for 1990, 2020, and 2030.PLoS neglected tropical diseases · 2021Article
- Emodepside targets SLO-1 channels of Onchocerca ochengi and induces broad anthelmintic effects in a bovine model of onchocerciasis.PLoS pathogens · 2021Article
- Clinical, serological and DNA testing in Bengo Province, Angola further reveals low filarial endemicity and opportunities for disease elimination.Parasite epidemiology and control · 2020Article
- Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study.The Lancet. Infectious diseases · 2020Observational
- Atypical Clinical Manifestations of Loiasis and Their Relevance for Endemic Populations.Open forum infectious diseases · 2019Article
- The World Health Organization 2030 goals for onchocerciasis: Insights and perspectives from mathematical modelling: NTD Modelling Consortium Onchocerciasis Group.Gates open research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 5 countries.
Funding
Abstract
backgroundOnchocerciasis elimination through mass drug administration (MDA) is hampered by coendemicity of Loa loa, as people with high L. loa microfilariae (mf) density can develop serious adverse events (SAEs) after ivermectin treatment. We assessed the geographical overlap of onchocerciasis and loiasis prevalence and estimated the number of coinfected individuals at risk of post-ivermectin SAEs in West and Central Africa from 1995 to 2025.
methodsFocusing on regions with suspected loiasis transmission in 14 countries, we overlaid precontrol maps of loiasis and onchocerciasis prevalence to calculate precontrol prevalence of coinfection by 5 km2 × 5 km2 pixel, distinguishing different categories of L. loa mf intensity. Using statistical and mathematical models, we predicted prevalence of both infections and coinfection for 2015 and 2025, accounting for the impact of MDA with ivermectin.
resultsThe number of people infected with onchocerciasis was predicted to decline from almost 19 million in 1995 to 4 million in 2025. Of these, 137 000 people were estimated to also have L. loa hypermicrofilaremia (≥20 000 L. loa mf/mL) in 1995, declining to 31 000 in 2025. In 2025, 92.8% of coinfected cases with loiasis hypermicrofilaremia are predicted to live in hypoendemic areas currently not targeted for MDA.
conclusionsLoiasis coinfection is a major concern for onchocerciasis elimination in Africa. We predict that under current strategies, at least 31 000 coinfected people still require treatment for onchocerciasis in 2025 while being at risk of SAEs, justifying continued efforts in research and development for safer drugs and control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.